



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,
Opp. PCI, Ankleshwar – 393 002,
Gujarat, India
Tel : (02646) 220774
Fax : (02646) 251291
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India.
Tel : (91-22) 26701050/1/2
Fax : (91-22) 26701053
Email: contact@samratpharmachem.in

September 14, 2020

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Outcome of the Board Meeting of the Company held today

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, September 14, 2020, the Board has considered and took on record the attached Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2020, which is enclosed herewith along with the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 18:00 hrs and concluded at 19:30 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar 393 002, Gujarat
Corp Office : 701/702 Business Square, M. A. Road, Andheri-West, Mumbai 400 058
CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 30 June, 2020


(Rupees in Lakhs)

Particulars	Quarter Ended		Year Ended	
	30-Jun-20 (Unaudited)	31-Mar-20 (Audited)	30-Jun-19 (Unaudited)	31-Mar-20 (Audited)
1 (a). Revenue from Operations	3,526.67	3,027.81	3,548.05	13,745.25
(b). Other Income	1.90	7.74	4.08	57.22
Total Revenue	3,528.57	3,035.55	3,552.13	13,802.47
2. Expenditure				
a) Cost of materials consumed	2,698.36	2,941.95	3,212.54	13,179.80
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	574.69	-155.93	-72.89	-618.06
d) Employee Costs	27.64	50.88	29.07	144.39
e) Interest	45.89	33.42	16.66	97.83
f) Depreciation & Amortisation expense	11.20	10.83	10.53	42.63
g) Other Expenses	64.25	96.73	101.43	376.16
Total Expenses	3,422.03	2,977.88	3,297.34	13,222.75
3. Profit before exceptional & extraordinary items & tax	106.54	57.67	254.79	579.72
4. Exceptional Items	0.00	-1.20	0.00	-1.20
5. Profit before extraordinary items & tax	106.54	56.47	254.79	578.52
6. Extraordinary items	0.00	0.00	0.00	0.00
7. Profit before tax	106.54	56.47	254.79	578.52
8. Tax expense				
a) Current Tax	-10.65	-45.13	-63.79	-172.51
b) Deferred Tax	-16.09	28.00	-3.99	17.69
Total Tax Expense	-26.74	-17.13	-67.78	-154.82
9. Profit (Loss) for the period after tax	79.80	39.34	187.01	423.70
10. Other Comprehensive Income (OCI)				
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	79.80	39.34	187.01	423.70
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97
13. Earnings per equity share				
a) Basic	2.58	1.27	6.05	13.71
b) Diluted	2.58	1.27	6.05	13.71

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 June, 2020
- The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Monday, 14 September 2020 at the Corporate Office of the Company.
- Figures for the previous period have been regrouped / reclassified, wherever necessary.

By order of the Board of Directors
For Samrat Pharmachem Limited


Rajesh Mehta
Executive Director
DIN: 00216731



Place : Mumbai
Date : 14 September 2020



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance


CA Nihar Dharod
Indirect Tax & Litigation

Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

To Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th June, 2020 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
2. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financials statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP
Chartered Accountants
Firm Reg: No.:109364W/W100143


CA. Miral H. Nagda
(Partner)
Membership No. 108135
UDIN : 20108135AAAABL6902
Place: Mumbai
Date: 14th September, 2020

